Interpersonal therapy versus antidepressant medication for treatment of postpartum depression and anxiety among women with HIV in Zambia: a randomized feasibility trial.
HIV infection
Zambia
antidepressive agents
anxiety
depression
postpartum
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
18
10
2021
accepted:
14
06
2022
entrez:
8
7
2022
pubmed:
9
7
2022
medline:
14
7
2022
Statut:
ppublish
Résumé
Postpartum depression (PPD) is a prevalent and debilitating disease that may affect medication adherence and thus maternal health and vertical transmission among women with HIV. We assessed the feasibility of a trial of interpersonal psychotherapy (IPT) versus antidepressant medication (ADM) to treat PPD and/or anxiety among postpartum women with HIV in Lusaka, Zambia. Between 29 October 2019 and 8 September 2020, we pre-screened women 6-8 weeks after delivery with the Edinburgh Postnatal Depression Scale (EPDS) and diagnosed PPD or anxiety with the Mini International Neuropsychiatric Interview. Consenting participants were randomized 1:1 to up to 11 sessions of IPT or daily self-administered sertraline and followed for 24 weeks. We assessed EPDS score, Clinical Global Impression-Severity of Illness (CGI-S) and medication side effects at each visit and measured maternal HIV viral load at baseline and final study visit. Retention, visit adherence, change in EPDS, CGI-S and log viral load were compared between groups with t-tests and Wilcoxon signed rank tests; we report mean differences, relative risks and 95% confidence intervals. A participant satisfaction survey assessed trial acceptability. 78/80 (98%) participants were retained at the final study visit. In the context of the COVID-19 pandemic, visit adherence was greater among women allocated to ADM (9.9 visits, SD 2.2) versus IPT (8.9 visits, SD 2.4; p = 0.06). EPDS scores decreased from baseline to final visit overall, though mean change was greater in the IPT group (-13.8 points, SD 4.7) compared to the ADM group (-11.4 points, SD 5.5; p = 0.04). Both groups showed similar changes in mean log viral load from baseline to final study visit (mean difference -0.43, 95% CI -0.32, 1.18; p = 0.48). In the IPT group, viral load decreased significantly from baseline (0.9 log copies/ml, SD 1.7) to final visit (0.2 log copies/ml, SD 0.9; p = 0.01). This pilot study demonstrates that a trial of two forms of PPD treatment is feasible and acceptable among women with HIV in Zambia. IPT and ADM both improved measures of depression severity; however, a full-scale trial is required to determine whether treatment of PPD and anxiety improves maternal-infant HIV outcomes.
Identifiants
pubmed: 35803896
doi: 10.1002/jia2.25959
pmc: PMC9270230
doi:
Substances chimiques
Antidepressive Agents
0
Banques de données
ClinicalTrials.gov
['NCT04094870']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25959Subventions
Organisme : FIC NIH HHS
ID : K01 TW010857
Pays : United States
Organisme : NIH HHS
ID : UL1TR002489
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH115806
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002489
Pays : United States
Organisme : NIMH NIH HHS
ID : 1R21MH115806
Pays : United States
Organisme : NICHD NIH HHS
ID : T32 HD075731
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009340
Pays : United States
Informations de copyright
© 2022 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
Med J Zambia. 2010;37(2):78-83
pubmed: 23226901
PLoS One. 2009 Jun 04;4(6):e5790
pubmed: 19495419
BMC Psychiatry. 2016 May 26;16:164
pubmed: 27228979
Clin Obstet Gynecol. 2009 Sep;52(3):483-97
pubmed: 19661763
PLoS One. 2020 Apr 28;15(4):e0231940
pubmed: 32343736
J Int AIDS Soc. 2021 Oct;24(10):e25823
pubmed: 34708929
Nat Rev Dis Primers. 2018 Apr 26;4:18022
pubmed: 29695824
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Int J Behav Med. 2022 Mar 8;:
pubmed: 35260947
Asian J Psychiatr. 2018 Oct;37:112-120
pubmed: 30173015
J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):410-5
pubmed: 23535294
Lancet Psychiatry. 2016 Oct;3(10):973-982
pubmed: 27650773
J Affect Disord. 2019 Dec 1;259:279-287
pubmed: 31454590
Trials. 2018 Mar 22;19(1):193
pubmed: 29566739
Clin Infect Dis. 2005 Feb 1;40(3):458-65
pubmed: 15668871
BMC Pregnancy Childbirth. 2015 Oct 12;15:258
pubmed: 26459335
Lancet. 2019 Jun 15;393(10189):e42-e43
pubmed: 30482607
Clin Neuropharmacol. 1993;16 Suppl 3:S32-44
pubmed: 8131153
Psychiatry (Edgmont). 2007 Jul;4(7):28-37
pubmed: 20526405
J Int Assoc Provid AIDS Care. 2014 Jul-Aug;13(4):335-41
pubmed: 23881909
JAMA. 2003 Jun 18;289(23):3117-24
pubmed: 12813117
J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):384-90
pubmed: 18091609
Br J Psychiatry. 1987 Jun;150:782-6
pubmed: 3651732
Pan Afr Med J. 2020 Sep 25;37:89
pubmed: 33244352
Public Health Rev. 2017 Dec 05;38:28
pubmed: 29450099
Cochrane Database Syst Rev. 2018 Apr 18;4:CD004363
pubmed: 29669175
J Affect Disord. 2019 Feb 15;245:524-532
pubmed: 30447565
BMC Fam Pract. 2007 Aug 29;8:49
pubmed: 17727730
J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):432-8
pubmed: 15764960
PLoS Med. 2021 Jan 11;18(1):e1003468
pubmed: 33428625
Gen Hosp Psychiatry. 2016 May-Jun;40:12-7
pubmed: 27079616